TPI Expects To Receive GMP From China's FDA By End Of 2014
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates that it expects to receive the formal Good Manufacturing Practice (GMP) certificate for its Qionglai Facility's (QLF) from the China Food & Drug Administration's (CFDA) by the end of December 2014. Prior to the official issuance of the GMP certificate, there is a public notice period which is likely to take place within this week. The public notice period is an important step of GMP certificate during which the pharmaceutical manufacturing facility's GMP application will be disclosed on the CFDA website. The public notice time will last for approximately 10 business days which is to be followed by immediate issuance of the GMP certificate. TPI is currently preparing for the smooth transition of production capacity from the current Longquan facilities to the new QLF immediately following the official issuance of GMP certificate.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.